Extended Use of Clomiphene Citrate in Induction of Ovulation in Polycystic Ovary Syndrome with Clomiphene Citrate Resistance | ||
| The Egyptian Journal of Hospital Medicine | ||
| Article 28, Volume 82, Issue 3, January 2021, Pages 567-573 PDF (497.66 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ejhm.2021.148562 | ||
| Authors | ||
| Mohammed Abd El Ghany Omara1; Nabih Ibrahim El Khouly1; Hend Talaat Salama2; Ayman El-Sayed Solyman1 | ||
| 1Obstetrics and Gynecology Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt | ||
| 2Obstetrics and Gynecology Department, Albagour General Hospital, Menoufia, Egypt | ||
| Abstract | ||
| Background: Clomiphene citrate (CC) is still holding its place as the first-line treatment for induction of ovulation in polycystic ovary syndrome (PCOS) patients. Objective: to assess the effect of extended clomiphene citrate on pregnancy outcomes of clomiphene resistant PCOS. Patients and methods: this study was conducted on 48 PCO patients with CC resistance attended to the Obstetrics and Gynecology Outpatient Clinic at Menoufia University and Al-Bajour General Hospitals, from April 2018 to February 2020. Patients were treated with an extended CC administration (150 mg for 10 days) to overcome anovulation. Result: There was highly significant change in follicle-stimulating hormone (FSH), luteinizing hormone (LH) and FSH/LH after extended CC treatment (p < 0.001). Also, serum progesterone and number of follicles were significantly increased after treatment compared to before treatment. Conclusion: CC extended is a safe, effective with minimal side effect, but low pregnancy rate was observed. Therefore, further studies with large number of PCO patients with CC resistant with addition of other drugs are required to investigate the improvement of the pregnancy rate. | ||
| Keywords | ||
| Clomiphene citrate resistance; Extended use; Rotterdam criteria | ||
|
Statistics Article View: 373 PDF Download: 634 |
||
